Artificial pancreas trial yields positive results
11 June 2012 17:44 in Scientific Developments/Breakthroughs
Scientists have published positive data from the first human clinical trial of a potentially revolutionary new artificial pancreas system.
A study conducted by Johnson and Johnson subsidiary Animas, in association with diabetes research charity JDRF, has yielded encouraging performance data for the new Hypoglycaemia-Hyperglycaemia Minimiser System.
The device was able to predict a rise and fall in blood glucose and correspondingly increase and decrease insulin delivery in a safe manner.
Animas' device - which incorporates a subcutaneous insulin pump, a continuous glucose monitor and special software to predict changes in blood glucose - is being developed with investigational device exemption approval from the US Food and Drug Administration.
Dr Aaron Kowalski, assistant vice-president of research at JDRF, said: "An artificial pancreas system that can not only detect, but can predict high and low blood sugar levels and make automatic adjustments to insulin delivery, would be a major advance for people with type 1 diabetes."
This comes after JDRF announced new partnerships with BD and Medtronic in recent weeks in order to continue progressing research in this area of technology.
Other news stories from 11/06/2012
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency